Metastasis Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.
J Pathol. 2015 Apr;235(5):760-72. doi: 10.1002/path.4490. Epub 2015 Jan 7.
Although many preclinical studies have implicated β3 integrin receptors (αvβ3 and αIIbβ3) in cancer progression, β3 inhibitors have shown only modest efficacy in patients with advanced solid tumours. The limited efficacy of β3 inhibitors in patients could arise from our incomplete understanding of the precise function of β3 integrin and, consequently, inappropriate clinical application. Data from animal studies are conflicting and indicate heterogeneity with respect to the relative contributions of β3-expressing tumour and stromal cell populations in different cancers. Here we aimed to clarify the function and relative contributions to metastasis of tumour versus stromal β3 integrin in clinically relevant models of spontaneous breast cancer metastasis, with particular emphasis on bone metastasis. We show that stable down-regulation of tumour β3 integrin dramatically impairs spontaneous (but not experimental) metastasis to bone and lung without affecting primary tumour growth in the mammary gland. Unexpectedly, and in contrast to subcutaneous tumours, orthotopic tumour vascularity, growth and spontaneous metastasis were not altered in mice null for β3 integrin. Tumour β3 integrin promoted migration, protease expression and trans-endothelial migration in vitro and increased vascular dissemination in vivo, but was not necessary for bone colonization in experimental metastasis assays. We conclude that tumour, rather than stromal, β3 expression is essential and is required early for efficient spontaneous breast cancer metastasis to bone and soft tissues. Accordingly, differential gene expression analysis in cohorts of breast cancer patients showed a strong association between high β3 expression, early metastasis and shorter disease-free survival in patients with oestrogen receptor-negative tumours. We propose that β3 inhibitors may be more efficacious if used in a neoadjuvant setting, rather than after metastases are established.
虽然许多临床前研究表明β3 整合素受体(αvβ3 和 αIIbβ3)与癌症进展有关,但β3 抑制剂在晚期实体瘤患者中的疗效仅为中等。β3 抑制剂在患者中的疗效有限可能是由于我们对β3 整合素的确切功能的理解不完整,因此临床应用不当。来自动物研究的数据存在冲突,表明不同癌症中β3 表达肿瘤和基质细胞群体的相对贡献存在异质性。在这里,我们旨在阐明β3 整合素在临床相关自发性乳腺癌转移模型中的功能及其对转移的相对贡献,特别强调骨转移。我们发现,肿瘤β3 整合素的稳定下调显着损害了自发性(而非实验性)骨和肺转移,而不影响乳腺中的原发性肿瘤生长。出乎意料的是,与皮下肿瘤相反,β3 整合素缺失的小鼠的肿瘤血管生成、生长和自发性转移没有改变。肿瘤β3 整合素促进了体外迁移、蛋白酶表达和跨内皮迁移,并增加了体内血管播散,但在实验性转移测定中并非骨定植所必需。我们得出的结论是,肿瘤而不是基质β3 表达是必需的,并且对于有效的自发性乳腺癌骨和软组织转移是早期必需的。因此,在乳腺癌患者队列的差异基因表达分析中,高β3 表达、早期转移和雌激素受体阴性肿瘤患者无病生存期较短之间存在很强的关联。我们提出,如果在新辅助治疗中使用β3 抑制剂,而不是在转移建立后使用,可能会更有效。